Published in Can Urol Assoc J on February 01, 2010
Cancer Care Ontario Guidelines for radical prostatectomy: striving for continuous quality improvement in community practice. Can Urol Assoc J (2012) 1.52
Oncological and functional outcomes of 722 robot-assisted radical prostatectomy (RARP) cases: The largest Canadian 5-year experience. Can Urol Assoc J (2014) 1.50
The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J (2012) 1.07
Impact of body mass index on perioperative outcomes during the learning curve for robot-assisted radical prostatectomy. Can Urol Assoc J (2010) 0.99
Perioperative, oncological and functional outcomes of the first robotic prostatectomy program in Quebec: Single fellowship-trained surgeon's experience of 250 cases. Can Urol Assoc J (2013) 0.98
No impact of blood transfusion on oncological outcome after radical prostatectomy in patients with prostate cancer. World J Urol (2014) 0.90
Patient Blood Management: A Patient-Orientated Approach to Blood Replacement with the Goal of Reducing Anemia, Blood Loss and the Need for Blood Transfusion in Elective Surgery. Transfus Med Hemother (2012) 0.82
Reporting the Canadian robotic experience: The outcomes and how we report them. Can Urol Assoc J (2013) 0.77
Positive surgical margins at radical prostatectomy: Population-based averages within PSA and Gleason strata. Can Urol Assoc J (2013) 0.76
Physician level reporting of surgical and pathology performance indicators: a regional study to assess feasibility and impact on quality. Can J Surg (2015) 0.75
Ensuring quality for radical prostatectomies in Canada. Can Urol Assoc J (2010) 0.75
Guidelines and quality outcomes in cancer surgery: Goals, expectations and reality television. Can Urol Assoc J (2012) 0.75
Why all prostate cancer surgery should include an adequate lymph node dissection. Can Urol Assoc J (2010) 0.75
Association between Allogeneic or Autologous Blood Transfusion and Survival in Patients after Radical Prostatectomy: A Systematic Review and Meta-Analysis. PLoS One (2017) 0.75
Variations in morbidity after radical prostatectomy. N Engl J Med (2002) 7.26
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology (2005) 4.71
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol (2003) 3.58
Variations among individual surgeons in the rate of positive surgical margins in radical prostatectomy specimens. J Urol (2003) 3.27
Variations among high volume surgeons in the rate of complications after radical prostatectomy: further evidence that technique matters. J Urol (2005) 2.98
The actual value of the surgical margin status as a predictor of disease progression in men with early prostate cancer. Eur Urol (2006) 2.71
Do margins matter? The prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol (2005) 2.69
Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol (2002) 2.66
Nerve sparing open radical retropubic prostatectomy--does it have an impact on urinary continence? J Urol (2006) 2.65
Detection of occult lymph node metastases in locally advanced node-negative prostate cancer. J Clin Oncol (2006) 2.55
Intra- and peri-operative outcomes comparing radical retropubic and laparoscopic radical prostatectomy: results from a prospective, randomised, single-surgeon study. Eur Urol (2006) 2.48
Potency, continence and complications in 3,477 consecutive radical retropubic prostatectomies. J Urol (2004) 2.15
Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol (1999) 2.07
Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol (2006) 2.02
Laparoscopic radical prostatectomy: oncological evaluation after 1,000 cases a Montsouris Institute. J Urol (2003) 1.90
Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol (2004) 1.85
Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J Urol (2002) 1.50
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology (1997) 1.50
Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology (2006) 1.46
The impact of surgical approach (nerve bundle preservation versus wide local excision) on surgical margins and biochemical recurrence following radical prostatectomy. J Urol (2004) 1.32
Randomized prospective evaluation of extended versus limited lymph node dissection in patients with clinically localized prostate cancer. J Urol (2003) 1.29
Probability of biochemical recurrence by analysis of pathologic stage, Gleason score, and margin status for localized prostate cancer. Urology (2003) 1.23
Radical prostatectomy: bladder neck preservation and puboprostatic ligament sparing--effects on continence and positive margins. Urology (2002) 1.21
Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol (2004) 1.20
The association between total and positive lymph node counts, and disease progression in clinically localized prostate cancer. J Urol (2006) 1.20
An operative and anatomic study to help in nerve sparing during laparoscopic and robotic radical prostatectomy. Eur Urol (2003) 1.19
Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys (1999) 1.15
Risk of positive margins and biochemical recurrence in relation to nerve-sparing radical prostatectomy. J Clin Oncol (2002) 1.10
Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology (1996) 1.10
Influence of nerve-sparing (NS) procedure during radical prostatectomy (RP) on margin status and biochemical failure. Eur Urol (2005) 1.09
Does the interval between prostate biopsy and radical prostatectomy affect the immediate postoperative outcome? BJU Int (2006) 1.09
Utilizing predictions of early prostate-specific antigen failure to optimize patient selection for adjuvant systemic therapy trials. J Clin Oncol (2000) 1.07
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era. J Urol (2005) 1.04
Positive surgical margins after radical retropubic prostatectomy: the influence of site and number on progression. J Urol (2002) 1.03
Site specific predictors of positive margins at radical prostatectomy: an argument for risk based modification of technique. J Urol (1998) 1.03
When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol (1997) 1.03
Laparoscopic radical prostatectomy: assessment after 550 procedures. Crit Rev Oncol Hematol (2002) 1.02
Prognostic significance of positive surgical margins in patients with extraprostatic carcinoma after radical prostatectomy. Cancer (2002) 1.02
Impact of surgical margin status on long-term cancer control after radical prostatectomy. BJU Int (2006) 1.00
Key issues in handling and reporting radical prostatectomy specimens. Arch Pathol Lab Med (2006) 0.97
The influence of serial sections, immunohistochemistry, and extension of pelvic lymph node dissection on the lymph node status in clinically localized prostate cancer. Eur Urol (2003) 0.95
Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur Urol (2002) 0.95
Lower urinary tract symptoms, urinary incontinence, sexual function and quality of life after radical prostatectomy and external beam radiation therapy: real life experience in Austria. World J Urol (2006) 0.94
Surgical modifications of radical retropubic prostatectomy to decrease incidence of positive surgical margins. J Urol (1998) 0.92
Evaluation of complications and results in a contemporary series of 300 consecutive radical retropubic prostatectomies with the anatomic approach at a single institution. Urology (2003) 0.92
Radical retropubic prostatectomy and blood transfusion. Mayo Clin Proc (2002) 0.91
Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. Urology (2004) 0.91
No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology (2004) 0.91
Prognostic consequences of the location of positive surgical margins in organ-confined prostate cancer. Urol Int (2003) 0.87
Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology (2000) 0.85
Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression. Urology (2003) 0.83
Initial incision of lateral pelvic fascia and early ligation of vascular pedicles during radical prostatectomy: potential to reduce positive margin rates. BJU Int (2005) 0.83
Perineural invasion in prostate cancer biopsies is not associated with higher rates of positive surgical margins. Prostate (2005) 0.83
Radical prostatectomy in a community practice. J Urol (2002) 0.83
A comparison of radical retropubic with perineal prostatectomy for localized prostate cancer within the Uniformed Services Urology Research Group. BJU Int (2001) 0.83
Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy. Urology (1998) 0.82
Comparison of bladder neck preservation to bladder neck resection in maintaining postrostatectomy urinary continence. Urology (1996) 0.82
The role of digital rectal examination, biopsy Gleason sum and prostate-specific antigen in selecting patients who require pelvic lymph node dissections for prostate cancer. Br J Urol (1996) 0.81
Is there a need for pelvic lymph node dissection in low risk prostate cancer patients prior to definitive local therapy? Eur Urol (2005) 0.80
Trends in prostate cancer incidence, hospital utilization and surgical procedures, Canada, 1981-2000. Can J Public Health (2006) 0.80
Radical perineal prostatectomy without pelvic lymphadenectomy: selection criteria and early results. J Urol (1996) 0.80
No difference in biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients. Urology (2000) 0.79
The changing age distribution of prostate cancer in Canada. Can J Public Health (2007) 0.78
Intra-operative prostate examination: predictive value and effect on margin status. BJU Int (2005) 0.77
Is a limited lymphadenectomy targeting obturator nodes alone an adequate procedure for Japanese men undergoing radical prostatectomy? Int J Urol (2005) 0.77
The staging pelvic lymphadenectomy: implications as an adjunctive procedure for clinically localized prostate cancer. Br J Urol (1997) 0.77
Cavernous nerve graft reconstruction during radical prostatectomy or radical cystectomy: safe and technically feasible. Prostate Cancer Prostatic Dis (2003) 0.77
Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol (2013) 4.75
Quality councils as health system performance and accountability mechanisms: the Cancer Quality Council of Ontario experience. Healthc Pap (2006) 4.14
Outcomes of small renal mass needle core biopsy, nondiagnostic percutaneous biopsy, and the role of repeat biopsy. Eur Urol (2011) 3.51
Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol (2008) 3.49
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol (2011) 3.36
30-day mortality and major complications after radical prostatectomy: influence of age and comorbidity. J Natl Cancer Inst (2005) 3.26
A framework for the identification of men at increased risk for prostate cancer. J Urol (2009) 3.07
Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors. J Am Coll Surg (2004) 2.97
Training carers of stroke patients: randomised controlled trial. BMJ (2004) 2.95
Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study. J Urol (2013) 2.65
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol (2006) 2.50
Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma. J Am Coll Surg (2006) 2.37
Accurate molecular classification of kidney cancer subtypes using microRNA signature. Eur Urol (2011) 2.29
Follow-up of patients with curatively resected colorectal cancer: a practice guideline. BMC Cancer (2003) 2.26
Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery (2006) 2.24
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
Defining surgical quality in gastric cancer: a RAND/UCLA appropriateness study. J Am Coll Surg (2013) 2.19
Variability in diagnostic opinion among pathologists for single small atypical foci in prostate biopsies. Am J Surg Pathol (2010) 2.16
AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology (2010) 2.09
Diminished efficacy of Bacille Calmette-Guérin among elderly patients with nonmuscle invasive bladder cancer. Urology (2011) 2.07
Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann Surg Oncol (2006) 2.02
Information needs of men on androgen deprivation therapy. BJU Int (2011) 2.02
Differences in stroke subtypes between black and white patients with stroke: the South London Ethnicity and Stroke Study. Circulation (2007) 2.01
Diagnostic accuracy of MRI for assessment of T category, lymph node metastases, and circumferential resection margin involvement in patients with rectal cancer: a systematic review and meta-analysis. Ann Surg Oncol (2012) 2.00
Digital imaging in pathology: whole-slide imaging and beyond. Annu Rev Pathol (2012) 1.89
Female infertility after ileal pouch-anal anastomosis for ulcerative colitis. Dis Colon Rectum (2004) 1.87
The management of thymoma: a systematic review and practice guideline. J Thorac Oncol (2009) 1.85
Randomized clinical trial of vitamin D3 doses on prostatic vitamin D metabolite levels and ki67 labeling in prostate cancer patients. J Clin Endocrinol Metab (2013) 1.81
An aggressive surgical approach leads to improved survival in patients with gallbladder cancer: a 12-year study at a North American Center. Ann Surg (2005) 1.76
The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels. BJU Int (2009) 1.75
Alternative strategies for stroke care: cost-effectiveness and cost-utility analyses from a prospective randomized controlled trial. Stroke (2003) 1.74
Optimal management of gastric cancer: results from an international RAND/UCLA expert panel. Ann Surg (2014) 1.61
Development of prostate cancer quality indicators: a modified Delphi approach. Can J Urol (2005) 1.59
Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology (2007) 1.58
Clinical significance of the positive surgical margin based upon location, grade, and stage. Urol Oncol (2010) 1.57
Efficacy of a second line luteinizing hormone-releasing hormone agonist after advanced prostate cancer biochemical recurrence. J Urol (2011) 1.54
Prostate cancers scored as Gleason 6 on prostate biopsy are frequently Gleason 7 tumors at radical prostatectomy: implication on outcome. J Urol (2006) 1.53
Does an integrated care pathway improve processes of care in stroke rehabilitation? A randomized controlled trial. Age Ageing (2002) 1.50
The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol (2004) 1.49
'Prostatic evasive anterior tumours': the role of magnetic resonance imaging. BJU Int (2009) 1.48
Standards for thoracic surgical oncology in a single-payer healthcare system. Ann Thorac Surg (2007) 1.48
Impact of multiparametric endorectal coil prostate magnetic resonance imaging on disease reclassification among active surveillance candidates: a prospective cohort study. J Urol (2012) 1.47
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy. Clin Cancer Res (2011) 1.46
TMPRSS2-ERG status is not prognostic following prostate cancer radiotherapy: implications for fusion status and DSB repair. Clin Cancer Res (2013) 1.45
Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men aged<or=55 years with favorable prostate cancer. Urology (2009) 1.45
Training care givers of stroke patients: economic evaluation. BMJ (2004) 1.44
Current textbooks and anatomy of the prostate--a case for an update. BJU Int (2009) 1.41
Impact of 5-alpha reductase inhibitors on men followed by active surveillance for prostate cancer: a time-dependent covariate reanalysis. Eur Urol (2013) 1.39
Predictors of failure after pancreaticoduodenectomy for ampullary carcinoma. J Am Coll Surg (2005) 1.39
Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma. J Clin Endocrinol Metab (2008) 1.37
Comparison of health-related quality of life 5 years after SPIRIT: Surgical Prostatectomy Versus Interstitial Radiation Intervention Trial. J Clin Oncol (2010) 1.37
Collaboration, communication, management, and advocacy: teaching surgeons new skills through the CanMEDS Project. World J Surg (2003) 1.37
Pancreatic resection for metastatic renal cell carcinoma: presentation, treatment, and outcome. Ann Surg Oncol (2003) 1.35
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
Impact of androgen-deprivation therapy on cognitive function in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.34
Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med (2004) 1.33
Impact of positive surgical margins after radical prostatectomy differs by disease risk group. J Urol (2010) 1.33
Prevalence of prostate cancer on autopsy: cross-sectional study on unscreened Caucasian and Asian men. J Natl Cancer Inst (2013) 1.32
Methylation of novel markers of fragile X alleles is inversely correlated with FMRP expression and FMR1 activation ratio. Hum Mol Genet (2010) 1.31
Warm water and cool nests are best. How global warming might influence hatchling green turtle swimming performance. PLoS One (2011) 1.29
Differences between urologists in United States and Canada in approach to bladder cancer. Urology (2005) 1.28
Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PLoS One (2009) 1.28
Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: Incorporating new agents into clinical practice. Can Urol Assoc J (2012) 1.27
Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology (2003) 1.26
Troubling outcomes from population-level analysis of surgery for upper tract urothelial carcinoma. Urology (2010) 1.25
The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J Mol Diagn (2012) 1.24
Correlation of histologic prognostic factors in core biopsies and therapeutic excisions of invasive breast carcinoma. Am J Surg Pathol (2003) 1.24
Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses. BJU Int (2008) 1.23
Publication rate of abstracts presented at the annual meeting of the American Urological Association. BJU Int (2004) 1.23
Canadian Association of General Surgeons and American College of Surgeons evidence based reviews in surgery. 14. Preoperative fasting for adults to prevent perioperative complications. Can J Surg (2005) 1.22
Canadian licensure for the use of digital pathology for routine diagnoses: one more step toward a new era of pathology practice without borders. Arch Pathol Lab Med (2013) 1.19
Recurrent pyogenic cholangitis with hepatolithiasis--the role of surgical therapy in North America. J Gastrointest Surg (2007) 1.18
Surgical margin status among men with organ-confined (pT2) prostate cancer: a population-based study. Can Urol Assoc J (2011) 1.17
Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy. Can J Urol (2003) 1.17
Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection. J Clin Oncol (2003) 1.16
Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. BJU Int (2010) 1.15
Papillary renal cell carcinoma within a renal oncocytoma: case report of an incidental finding of a tumour within a tumour. J Clin Pathol (2007) 1.14
Fecal immunochemical tests compared with guaiac fecal occult blood tests for population-based colorectal cancer screening. Can J Gastroenterol (2012) 1.14
Transperitoneal laparoscopic prostatectomy does not increase small bowel within the target volume for postoperative radiotherapy. J Urol (2009) 1.13
Influence of hospital characteristics on operative death and survival of patients after major cancer surgery in Ontario. Can J Surg (2006) 1.12
Screening with prostate specific antigen and metastatic prostate cancer risk: a population based case-control study. J Urol (2005) 1.12